Targeted metabolomics requires accurate and precise quantification of candidate biomarkers, often through tandem mass spectrometric (MS/MS) analysis. Differential isotope labeling (DIL) improves mass spectrometric (MS) analysis in metabolomics by derivatizing metabolites with two isotopic forms of the same reagent. Despite its advantages, DIL-liquid chromatographic (LC)-MS/MS can result in substantial increase in workload when fully validated quantitative methods are required. To decrease the workload, we hypothesized that single point calibration or relative quantification could be used as alternative methods. Either approach will result in significant saving in resources and time. To test our hypothesis, six urinary metabolites were selected as model compounds. Urine samples were analyzed using a fully validated multipoint dansyl chloride-DIL-LC-MS/MS method. Samples were reprocessed using single point calibration and relative quantification modes. Our results demonstrated that the performance of single point calibration or relative quantification was inferior, for some metabolites, to multipoint calibration. The lower limit of quantification failed in the quantification of ethanolamine in most of participant samples using single point calibration. In addition, its precision was not acceptable in one participant during serine and ethanolamine quantification. On the other hand, relative quantification resulted in the least accurate data. In fact, none of the data generated from relative quantification for serine was comparable to that obtained from multipoint calibration. Finally, while single point calibration showed an overall acceptable performance for the majority of the model compounds, we cannot extrapolate the findings to other metabolites within the same analytical run. Analysts are advised to assess accuracy and precision for each metabolite in which single point calibration is the intended quantification mean.
Introduction
Metabolomics encompasses the identification and quantification of all possible endogenous and exogenous metabolites in a biological sample [1] [2] [3] . Biomarker discovery is a key application in metabolomics that aims to improve disease diagnosis and prognosis while also assessing therapeutic efficacy and toxicity [1] [2] [3] [4] . Metabolomics studies flow sequentially from untargeted to targeted platforms [5] [6] [7] . Unlike screening in the untargeted approach, targeted quantification of preselected metabolites requires a robust methodology usually with multiple reaction monitoring (MRM) acquisition [5] [6] [7] [8] . Targeted analysis is typically conducted by coupling tandem mass spectrometry (MS/MS) to gas chromatography (GC) or liquid chromatography (LC) [5] [6] [7] [8] .
The lack of well-established analytical frameworks for absolute quantification is a bottleneck in the biomarker qualification process [9] [10] [11] [12] [13] . Contrary to method validation for xenobiotics, available guidelines [14, 15] are not well suited to address all challenges with endogenous metabolite quantification. Consequently, there has been confusion on the extent of method validation needed to meet regulatory requirements [9] [10] [11] [12] . A Bfit-for-the-purpose^approach, achieving minimum validation criteria, has been deemed adequate for preliminary biomarker discovery experiments. However, methods designated for clinical decision-making require full validation to ascertain accuracy, precision, specificity, robustness, and stability [9] [10] [11] [12] .
In comparison with multipoint calibration, single point calibration involves the use of a single reference solution for the quantification of the target analyte. It assumes that the response of the analyte and the detector is linear to the analyte's concentration and the hypothetical calibration curve has a zero y-intercept [16, 17] . Single point calibration has been frequently used [18] [19] [20] [21] [22] [23] [24] [25] and it represents a compromise between validation rigidity, workload, and speed of data acquisition, thus providing semi-quantitative data [18] . Inaccuracies from single point calibration have been reported, citing low analytes concentration [19] or nonlinear calibration models [20] , as possible reasons. On the contrary, it has demonstrated comparable performance to multipoint calibration for quantifying analytes in biological fluids [21] [22] [23] , pharmaceutical preparations [24] , and tissue extracts [22, 25] .
Differential isotope labeling (DIL) in metabolomics, pioneered by L. Li, has been exploited to address many typically encountered challenges, including matrix interference and internal standard (IS) availability [26] [27] [28] . Using DIL, the derivatizing reagent is synthesized into light and heavy (deuterium or 13 C-labeled) forms [27] [28] [29] [30] [31] [32] [33] [34] [35] . The simultaneous derivatization of the analyte with both forms generates two isotopologue products that when mixed are detected as a peak pair by mass spectrometry (MS) [27] [28] [29] [30] [31] [32] [33] [34] . Derivatizing reagents targeting specific submetabolomes, such as dansyl chloride (DNS-Cl) (alcohols, amines, and phenols) [27, 29] , p-dimethylaminophenacyl bromide (acids) [28, 30] , dansyl hydrazine (carbonyl) [31] , and bromoacetonylquinolinium bromide (thiols) [32] are continuously introduced to DIL technique, increasing its usefulness in metabolomics. DIL is used for both absolute and semi-quantification purposes ( Fig. 1 ) [27] [28] [29] [30] [31] [32] [33] [34] [35] . However, absolute quantification [28, [35] [36] [37] has been an unfavorable option for researchers seeking rapid quantitative metabolomics data. This can be attributed to the additional workload for optimizing different reaction conditions along with the routine optimization of chromatographic/MS systems and the extensive validation needed prior to sample analysis [14, 15] . Accordingly, DIL has been mostly exploited in semi-quantification, or Brelative quantification^as described within the metabolomics society ( Fig. 1) [27, 32] .
We have recently developed an LC-MS/MS method for the absolute quantification of 19 amine-and phenolcontaining urinary metabolites using DIL with 12 C 2 / 13 C 2 -DNS-Cl [37] . The method was fully validated according to regulatory guidelines [14, 15] . However, a typical batch for clinical data acquisition would necessitate around 28 non-patient injections (around 11 h) of calibration standards, quality control (QC) samples, blanks, and system suitability samples [37, 38] , leading to an increased analysis time. Accordingly, we decided to pursue a comparative study between three different quantification modes using DIL-LC-MS/MS, where the performance of single point calibration or relative quantification was compared to the validated multipoint calibration method [37] . We hypothesized that these methods could provide accurate and precise analytical data, which would subsequently result in significant reduction in the required resources for high throughput targeted DIL-LC-MS/MS metabolomics. However, our hypothesis was not valid for the entire set of pilot metabolites selected for this study. Based on our findings, the robustness of single point calibration for the quantification of the remaining 13 metabolites was unpredictable and could not be extrapolated. Consequently, we opted not to further expand the current study by including the remaining set of the 19 metabolites [37] and a conclusion was drawn to pursue our future metabolomics research in the multipoint calibration mode. This work represents the first comparison of the analytical performance of three DIL-based targeted methods for metabolomics application.
Experimental

Materials and reagents
12
C 2 / 13 C 2 -DNS-Cl were synthesized as previously described [37] . All reagents and reference standards are detailed in our recent work [37] .
Urine sample collection
Participants (n = 7) were enrolled after obtaining their written informed consent as approved by the University of Saskatchewan's biomedical research ethics board (Bio# 13-89). Random mid-stream urine samples were collected from healthy male participants (25-40 years of age) currently not taking any form of medications. Urine specimen cups (Starplex Scientific Inc., ON, CA) were frozen at − 80°C shortly after collection and samples were subjected to 1 freeze-thaw cycle in which they were divided into aliquots in 1.5-mL micro centrifuge tubes (Fischer, CA). A pooled urine sample was prepared by mixing equal aliquots from five participants.
Standards derivatization
The preparation of underivatized individual standards, underivatized working standards mixture, and derivatized standards mixture was done as previously reported [37] . Briefly, for the derivatized standards, i.e.,
12
C 2 -DNS-analytes stock solution preparation; 50 μL from the working stock solution of the 19 standards were mixed with 30 μL bicarbonate/carbonate buffer (pH 9.4, 0.5 M) and 40 μL 12 C 2 -DNS-Cl (10.13 mg/mL in acetonitrile (ACN)). The mixture was heated at 60°C for 30 min and excess DNS-Cl was quenched with 10 μL 0.25 M NaOH with further heating at 60°C for 10 min. Seventy microliters of 300 mM formic acid (FA) in 50% ACN was added for medium acidification [37] . These derivatization steps, with the use of the appropriate isotopic form of DNS-Cl, are common between Only for the preparation of 13 C 2 -DNS-ISs stock solution, used in multipoint and single point calibrations, the addition of 300 mM FA in 50% ACN was followed by further dilution with 50 μL of 50% ACN. This dilution step was previously optimized in order to achieve the validated concentration of the ISs in the final mixtures [37] . Tenmicroliter aliquots from the aforementioned solution were used for spiking purposes in single and multipoint calibrations [37] . We have previously validated the suitability of the Bsurrogate urine^in simulating real derivatized urine [37] . The surrogate urine is used for the preparation of multipoint calibration standards and QC samples and it is prepared following the same derivatization steps described for 12 C 2 -DNSanalytes solution. However, 50 μL of pooled urine sample (7 patients) were used instead of the working stock solution and 30 μL ACN substituted the derivatizing reagent [37] . This matrix is meant to compensate for the absence of metabolitefree urine needed for method validation.
For relative quantification, only 12 C 2 -DNS-analytes solution is needed and was prepared similar to multipoint calibration. The produced 12 C 2 -DNS-analytes solution was further mixed with equal volume from 13 C 2 -DNS-pooled urine prepared as described below.
Urine derivatization
Urine aliquots were thawed to room temperature, diluted twofold with ACN, vortexed, and centrifuged at 13,000 rpm for 10 min prior to derivatization. Multipoint and single point quantification required the preparation of 12 C 2 -urine samples [37] . Fifty microliters of the supernatant solution of each urine sample (seven participants and one pooled urine sample) were derivatized as described for 12 C 2 -DNS-analytes solution. Following the addition of 300 mM FA in 50% ACN, 50 μL of each reacted urine mixture were diluted with 50 μL 50% ACN containing 10 μL 13 C 2 -DNS-ISs. The solutions were transferred into HPLC vials equipped with 100-μL glass inserts for analysis [37] . For relative quantification, additional 13 C 2 -pooled urine was prepared. After the addition of 300 mM FA in 50% ACN in 12 C 2 -urine or 13 C 2 -pooled urine, equal portions of both isotopic solutions were mixed for HPLC analysis.
Instrumentation
The validated method developed in our previous work [37] has been partially validated on a 1290 Agilent UPLC system (Mississauga, ON, Canada) interfaced to an AB Sciex 6500 API QTRAP instrument (AB Sciex, Concord, ON, Canada). A 1290 Agilent autosampler set at 4°C was used to deliver 5-μL samples for separation on a Kinetex C18 column mobile phase system, composed of (A) 5% ACN in 0.1% FA and (B) 0.1% FA in ACN, was used for metabolites separation in 25 min at a flow rate of 250 μL/min. The gradient system was as follows: t = 0, 90% A, t = 6, 85% A, t = 19, 35% A, t = 20, 35% A, t = 20.1, 90% A, and t = 25, 90% A.
Quantification was achieved using MRM scan mode and positive electrospray ionization (ESI). The monitored precursor ion → product ion transition for each 12 + → m/z 172.10. A qualifier diagnostic product ion was monitored for each 12 C 2 -DNSanalyte to confirm its identity, shown in Table 1 . The following parameters were optimized: turbo spray ion source temperature = 550°C, ion spray voltage = 5.5 kV, curtain gas = 30, collision gas = 9, nebulizer gas = 50, heater gas = 50, entrance potential = 10, collision exit potential = 13, transition dwell time = 20 msec, and cycle time = 1.4504 sec. The collision energy (CE) and declustering potential (DP) were separately optimized for each analyte (Table 1) . Data processing was achieved on Analyst software, version 1.6.2 (AB Sciex, Concord, ON, Canada), and SPSS software (version 24).
Metabolite selection
Based on our previous experience with human urine quantitative analysis [37] , we chose 4 metabolites: valine (VAL), tryptophan (TRP), serine (SER), and ethanolamine (ETNH 2 ). Each met at least three of the following criteria: (A) the metabolite is typically present in urine below its upper limit of quantification (ULOQ), and does not require additional sample dilution; (B) the metabolite is not seen at a concentration below the lower limit of quantification (LLOQ); (C) the metabolite's concentration is known to vary greatly among participant samples regardless of the participant's hydration status; and (D) the average concentration of the metabolite in pooled urine sample was in the middle range of the calibration curve.
The performance of the single point and relative quantification methods was further challenged through the inclusion of sarcosine (SAR) and lysine (LYS), which we have found to be present in urine towards the lower end of their linearity ranges. The selection criteria were biased towards the Bbest performing^metabolites. Such bias ensured that the variations in metabolite concentration would reflect true differences in performance across different quantification methods. Metabolites that might compromise the power of the analysis due to their trace levels (below LLOQ) were excluded, so as those that might introduce an error in the comparative study due to their additional sample preparation (above ULOQ).
Metabolite quantification
Multipoint calibration
Absolute quantification requires the use of calibration and QC samples (Fig. 1a) . Preparation of such solutions was done in accordance with our published protocol [37] . Eight-point calibration curves were generated by plotting peak area ratios of 12 C 2 -DNS-analytes and 13 C 2 -DNS-ISs against the corresponding 12 C 2 -DNS-analytes concentrations (Table 1) . Linear regression equations were generated using the sum of least squares with 1/x 2 weighing, a factor previously optimized during method validation [37] . QC samples were prepared at three different levels: lower QC (LQC), middle QC (MQC), and high QC (HQC) ( Table 1) .
Single point calibration
Raw data generated from Analyst software, version 1.6.2 was reprocessed for single point calibration. Since in real practice, each calibration curve point or QC sample can serve as a calibrator for analyte quantification (Fig. 1a ), metabolites were quantified using all calibration points and all three QC levels. There are differences in the linearity range optimized for each metabolite based on its levels in urine [37] . As such, the concentration of the calibrators is expressed in terms of fold concentration to the LLOQ. Calibrators (Table 1) . Peak area ratios of 12 C 2 -DNS-analytes to 13 C 2 -DNS-ISs in calibrators and individual urine samples were the basis for metabolite quantification (section BStatistical data analysis^).
Semi Brelative^quantification
Relative quantification was achieved in two sequential steps as previously reported (Fig. 1b) [27] . In the first step, the selected metabolites were quantified in pooled urine relative to their standards. In the second step, the quantified metabolites in pooled urine were used to determine their concentration in individual urine samples. For the quantification of metabolites in pooled urine (Step 1), three different volumes from 12 C 2 -DNS-analytes solution, producing final concentrations equivalent to calibrators [133.3×], [83.3×], and [2.67×], were properly diluted to 50 μL with 50% ACN and were separately mixed with 50 μL of 13 C 2 -pooled urine sample. The concentrations of the selected 13 C 2 -DNS-urinary metabolites were determined using absolute peak area comparison against each 12 C 2 -DNS-analyte calibrator (section BStatistical data analysis^). In step 2, 50 μL of 13 C 2 -pooled urine sample were mixed with an equal volume of individual 12 C 2 -urine Quantifier product ion = m/z 170.1 sample (Fig. 1b) . Quantification of metabolites in individual urine samples was also achieved through absolute peak area comparison (section BStatistical data analysis^).
Statistical data analysis
Data processing for absolute quantification was conducted using Analyst software, version 1. 
Results and discussion
This work was designed to address four questions in a DIL-LC-MS/MS targeted metabolomic workflow used for biomarker qualification. First, if an analytical method has been fully validated using multipoint DIL-LC-MS/MS, could metabolites be quantified with similar accuracy and precision, using single point calibration? This would substantially reduce instrument time, the number of calibration standards and the QC samples to be prepared. Second, would the choice of the single calibrator point (low vs. high and/or proximity to analyte concentration in a sample) affect the accuracy? Third, if the DIL-LC-MS/ MS method was used with relative quantification, would the knowledge of the dynamic range of the mass spectrometer along with the optimization of the derivatization reaction solely suffice for the acquisition of data with acceptable accuracy and precision? Finally, would the exclusion of individual urine samples from the pooled urine sample compromise the accuracy and precision of relative quantification? This is particularly important when new participants are still being recruited during the biomarker validation process. Table 1 summarizes the optimized MS parameters and the linearity ranges [37] of the selected metabolites. Figure 2 shows two representative calibration curves for ETNH 2 and SER. All eight calibration points for all metabolites were within 15% of their respective nominal values, indicating acceptable calibration curves [14, 15] for quantification (data not shown). Table 2 compiles the accuracy and precision of the LQC, MQC, and HQC samples, obtained during participant sample analysis. As seen in Table 2 , all QC samples were within 15% of their respective nominal values. In addition, their relative standard deviation (RSD%) was below 15%, indicating that the analytical runs met regulatory guidelines during clinical data acquisition [14, 15] . Details on the validation process of the multipoint calibration method are beyond the scope of this article; however, readers are advised to refer to our previously published work [37] . Urine samples from seven individuals and a pooled urine sample from five participants were analyzed using our previously validated multipoint calibration DIL-LC-MS/MS method [37] . Table 3 summarizes the concentrations of the metabolites in these samples. Calculated RSD% demonstrates high precision of the measurements (below 15%), with the exception of SER in participant 5 in which RSD% was 15.9% (Table 3 ). The concentration of TRP in participant 3 was above the ULOQ and was omitted from the calculations. Similarly, SAR in participant 1 was lower than the LLOQ and data from this participant for SAR was excluded ( Table 3) . As expected, the selected metabolites with the exception of SAR and LYS vary greatly in their concentration among the participant samples as well as in their distribution within their calibration ranges (Fig. 3) .
Multipoint calibration method
Single point calibration method
Results using QC samples Single point calibration was achieved by mathematical manipulation of the raw dataset obtained from the multipoint calibration method (Eq. 1). Similar to multipoint calibration where QC samples are used for quality assessment, QC samples were also used to evaluate the performance of the eight individual calibration standards as single point calibrators ( Table 4 ). The acceptance criteria established for bioanalytical method validation was adopted [14, 15] , in which accuracy values within ± 15% and RSD% below 15% are deemed acceptable. The performance of single point calibration was found inferior to that of the multipoint calibration for LYS, SER, and ETNH 2 , in which 3 out of 8 calibrators failed to demonstrate acceptable accuracy in at least one QC measurement ( Fig. 2 Representative calibration curves generated from the multipoint calibration method for the quantification of ETNH 2 (Fig. 2) , which was not the case. On the other hand, the accuracy of calibrator [1×] (equivalent to LLOQ) was acceptable for all metabolites with the exception of ETNH 2 , in which accuracies less than 85% were obtained for the MQC and HQC levels ( Table 4) .
and SER
As for the methods' precision, the criterion in all metabolites was met at all levels, and therefore was comparable to multipoint calibration from a validation standpoint (Table 4) . However, one interesting observation is that the highest RSD% variation for the LQC and HQC in SAR, VAL, TRP, ETNH 2 , and LYS were mostly generated from (Table 4) . Overall, the values generated from multipoint calibration were more accurate and precise that that generated from single point calibration (Tables 2 and 4) .
Results using participants' samples
The accuracy and precision of the participants' data generated using single point calibration were evaluated. Metabolites were quantified using individual calibrators 7×], were also used for quantification, as any standard solution can serve as a calibrator for data acquisition in single point calibration. Concentration of the metabolites generated from multipoint calibration was used as a benchmark and compared against those generated using single point calibration. With the exception of ETNH 2 , all calibrators resulted in acceptable accuracies, in which bias values were less than ± 15% [14, 15] (Fig. 4) . VAL concentration in participant 3, generated from calibrator [33.3×], had the highest deviation from multipoint calibration (− 14.8% bias) (Fig. 4) . The average bias values among all participants for SAR, VAL, TRP, and LYS were the highest with calibrator [3.3×]. Contrary to expectation [39] , we have found that the choice of calibrator that is in close proximity to the concentration of the analytes in urine samples did not result in the most accurate results for low concentration metabolites. Another concerning findings for accuracy using single point calibration were observed with ETNH 2 . First, calibrator [1×; i.e., LLOQ] resulted in unacceptable accuracy values among the majority of the samples, with an average bias of − 18.3% (Fig. 4) . This can be explained by the fact that the LLOQ is usually the calibration point in which validation criteria [14, 15] allows for wider accuracy acceptance limit (± 20% instead of ± 15%). The second observation is that 7 out of the 10 calibrators (excluding [1×]) failed to demonstrate acceptable accuracy in ETNH 2 measurements in pooled urine, where a maximum bias of − 21.3% was observed with calibrator [2.7×] (Fig. 4) . We could not draw an explanation for this observation. In fact, the inadequate performance of most calibrators in measuring ETNH 2 had a direct impact on the conclusion of accuracy for single point calibration. As such, we cannot exclude the probability that other metabolites [37] , not investigated within this study, might not be correctly quantified when single point calibration is used. Therefore, it is extremely important to investigate the performance of each metabolite, individually, using various calibrators prior to the consideration of single point calibration for regular data acquisition.
We then looked at the precision of single point calibration, and found it inferior to multipoint calibration for ETNH 2 , LYS, and SER (Fig. 5) . Calibrator [1×] resulted in marginally unacceptable RSD% of 15.9 and 15.3% for ETNH 2 and LYS, respectively. This was not unexpected from this LLOQ calibrator, where higher RSD% values (< 20%) are acceptable by the regulatory agencies during method validation of multipoint calibration [14, 15] . In addition to ETNH 2 and LYS, the highest RSD% values (still less than 15%) were observed with calibrator [1×] in TRP and SAR (Fig. 5) . Again, the relative inferior precision of this calibrator is important for LYS and SAR, in which a calibration point close to the analyte in real samples might not be the optimum point for precise data generation. Regardless of the calibrator used, the RSD% values in SER were similar per participant (Fig. 5) . Moreover, most calibrators resulted in unacceptable precision of SER measurements in participants 2 and 5 (RSD%; 15.2%-17.1%). In general, while the 11 calibrators resulted in acceptable precision in the majority of the metabolites in the analyzed samples, the RSD% values were relatively higher in single point calibration in comparison with multipoint calibration (Fig. 5) .
Relative quantification
We tailored our validated LC-MS/MS method [37] to quantify metabolites in a relative mode using Eqs. 2 and 3 [27] (Fig. 1b) , rather than the use of 13 C 2 -isotopic form as an internal standard (Fig. 1a) . We hypothesized that the proximity of metabolite concentrations in pooled urine sample to that of the spiked 12 C 2 -DNS-analytes could also influence the accuracy and precision of the measurements. (Fig. 1b) .
We were also concerned that the exclusion of individual urine samples from the pooled urine sample might compromise the accuracy and precision of relative quantification. This is particularly important when new participants are still being recruited during the biomarker validation process. In fact, the inability to pool all samples prior to analysis, for instance due to different times and locations of analysis, has been proposed as a potential impediment to the use of pooled control urine in large scale metabolomics [40] . As such, we created a sample pooled from five participants and left two out for later individual comparison. The pooled urine was then used to quantify all individual urine samples, including the excluded samples.
Relative quantification was very precise but showed inaccuracies in measurements more than single point calibration (Fig. 6) data (i.e., within ± 15%) for SAR, LYS, and TRP in at least three out of eight samples. On the other hand, the lowest calibrator, i.e., [2.7×] , was the only standard producing accurate measurements for LYS, SAR, and TRP in all urine samples (Fig. 6 ). While this observation can be justified by the low concentration of LYS and SAR in individual and pooled urine, Table 1 ) and single point calibration (using each calibration solution [1×] to [200×] and QC solutions (three levels) as calibrators, Eq. 1). Y-axis represents the RSD% ranges obtained from eight urine samples each processed in triplicates; the upper and lower whiskers represent higher and lower RSD% ranges, respectively. The box represents the interquartile range of RSD% values and the median is expressed through the vertical line within the box. Participants are represented by BP^, while BPU^stands for pooled urine an extrapolation to TRP, a widely distributed metabolite among patients and its linearity range (Fig. 3) , was not applicable. Finally, none of the tested calibrators produced accurate results in SER measurements in six out of eight samples (Fig. 6) .
In contrast to accuracy, precision of relative quantification was comparable to that of multipoint calibration. As shown in the error bars of Fig. 6 , all measurements were deemed precise with a RSD% of less than 15%. An exception was observed with calibrators [2.7×] and [133.3×] that resulted in high RSD% (18.3 and 16%) in participants 7 and 2, respectively, during SER quantification. Interestingly, unlike single point calibration, participant 7 consistently demonstrated the highest RSD% in all metabolites and with all calibrators. This observation could be attributed to the exclusion of this participant from the pooled urine sample. Therefore, the pooled matrix might not reflect the real matrix effect experienced within this participant. However, since this observation was not consistent with participant 6, who was also excluded, random error could also justify the higher dispersion of RSD%. The limited number of excluded participant samples hinders the decisive conclusion on such observation.
Conclusion
Our comparison of single point calibration and relative quantification to a multipoint validated DIL-LC-MS/MS method demonstrated shortcomings. We initially hypothesized that single point calibration would serve as an excellent substitute to multipoint calibration in the selected analytes and would not necessitate further testing of other metabolites [37] . Unfortunately, this hypothesis was not correct due to inconsistent performance across all investigated metabolites. Therefore, we recommend that if single point calibration is to be used for clinical data acquisition, it requires assessment on case-by-case basis. This would require investigation of the quality of the data for each metabolite using larger cohorts of samples. In addition, the results herein cannot be extrapolated to the same metabolites when a different derivatizing reagent or matrix is employed. The calibration mode had more influence on the accuracy of the data than its precision. Surprisingly, we did not find the accuracy of single point calibration to be dependent on the closeness of the analyte concentration to that in the sample. Further, the inaccuracy with ETNH 2 emphasizes that results from one calibrator might not be applicable to other metabolites beyond this study. In general, we recommend against the use of the LLOQ, even if the metabolite of interest lies within the lower range of the linear curve. In addition, unless established via experimentation that a specific calibrator is inaccurate and/or imprecise, any calibrator could theoretically serve as an adequate single point calibration standard for quantification, regardless of its concentration proximity to the metabolite of interest.
In regard to relative quantification, this method was less accurate in comparison to single point calibration. However, it has value in preliminary semi-quantitative analysis (e.g., screening metabolites for possible biomarker targets), which then would require validation. One possible explanation is the dependence of the results on the values obtained from pooled urine. Errors within the pooled urine metabolite quantification are further augmented in individual samples. Therefore, the quantification of the metabolite in the pooled urine sample represents the most critical step, upon which the accuracy of the rest of the analyses are dependent. For instance, in SAR, LYS, VAL, and TRP, the calibrator that resulted in the most accurate quantification values in pooled urine was also associated with the highest accuracy in participant samples. Using the absolute peak areas can also be another potential source of error, where the matrix in which the pooled urine sample is quantified, is different from that of the individual urine samples. Exclusion of samples from the pooled matrix can also be a potential source of lower quality data [40] .
Finally, this study was biased towards metabolites whose concentrations were already known to typically fall within the constructed calibration curve. While an inconsistent difference in the investigated quantification methods was demonstrated, such difference is expected to be further amplified in situations with highly concentrated metabolites that typically require dilution (e.g., histidine, alanine, and glycine) [37] . The same would apply to metabolites which frequently fall below their LLOQ (e.g., 1-methylhistamine) [37] . While a general conclusion on relative quantification or single point calibration cannot be made, based on our study findings, we advise the analytical community to pursue precautions when dansylation is employed for targeted urine metabolomics purposes.
